Literature DB >> 8667072

Hepatic artery injection of Yttrium-90-lipiodol: biodistribution in rats with hepatoma.

S J Wang1, W Y Lin, W Y Lui, M N Chen, Z T Tsai, G Ting.   

Abstract

UNLABELLED: In this study, we analyzed the biodistribution of 90Y-lipiodol in rats with liver tumors (hepatoma) following hepatic arterial injection.
METHODS: Sixteen male Sprague-Dawley rats with liver tumors were killed at 1, 24, 48 and 72 hr (four rats at each time) after injection of approximately 0.1 mCi 90Y-lipiodol through the hepatic artery, respectively. Samples of tumor, liver, spleen, skeletal muscle, lung, kidney, bone, whole blood and testis were obtained and counted to calculate the tissue concentrations (%ID/g).
RESULTS: We found that the radioactivity in the liver tumor was high at 1 and 24 hr and then declined slowly. The biological half-time was 84.1 hr. The radioactivity in normal liver tissue was also high at 1 hr but was significantly lower than that in the tumor. The biological half-time was 38.5 hr. The ratio of tissue concentration between liver tumor and normal liver tissue (T/N ratio) was 3.03 at 1 hr and rose to 6.45 at 72 hr. The radioactivity in the lung was almost as high as in normal liver tissue at 1 hr and declined rapidly with a biological half-time of 25.6 hr. The activity levels of the kidney were moderate at 1 hr and remained at almost the same level throughout the study. A moderate concentration of radioactivity in bone was noted within the first 24 hr. The concentration, however, rose over the ensuing time. The concentration of radioactivity in skeletal muscle, spleen, testis and whole blood was quite low.
CONCLUSION: Following hepatic arterial injection of 90Y-lipiodol, tracer uptake in liver tumor was high and tumor retention was lengthy. Consequently, large radiation doses could be delivered to the tumor. We suggest that 90Y-lipiodol is a potential agent in the treatment of liver malignancy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8667072

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  7 in total

Review 1.  Bench-to-clinic development of imageable drug-eluting embolization beads: finding the balance.

Authors:  Andrew L Lewis; Sean L Willis; Matthew R Dreher; Yiqing Tang; Koorosh Ashrafi; Bradford J Wood; Elliot B Levy; Karun V Sharma; Ayele H Negussie; Andrew S Mikhail
Journal:  Future Oncol       Date:  2018-06-26       Impact factor: 3.404

2.  Highly malignant intra-hepatic metastatic hepatocellular carcinoma in rats.

Authors:  Yang Guo; Rachel Klein; Reed A Omary; Guang-Yu Yang; Andrew C Larson
Journal:  Am J Transl Res       Date:  2010-11-01       Impact factor: 4.060

Review 3.  Treatment of hepatocellular carcinoma by means of radiopharmaceuticals.

Authors:  Bieke Lambert; Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-08       Impact factor: 9.236

4.  (188)Re-SSS/Lipiodol: Development of a Potential Treatment for HCC from Bench to Bedside.

Authors:  Nicolas Lepareur; Valérie Ardisson; Nicolas Noiret; Etienne Garin
Journal:  Int J Mol Imaging       Date:  2012-02-22

5.  Therapeutic and scintigraphic applications of polymeric micelles: combination of chemotherapy and radiotherapy in hepatocellular carcinoma.

Authors:  Ying-Hsia Shih; Cheng-Liang Peng; Ping-Fang Chiang; Wuu-Jyh Lin; Tsai-Yueh Luo; Ming-Jium Shieh
Journal:  Int J Nanomedicine       Date:  2015-12-16

Review 6.  Therapeutic Strategies in HCC: Radiation Modalities.

Authors:  R Gallicchio; A Nardelli; P Mainenti; A Nappi; D Capacchione; V Simeon; C Sirignano; F Abbruzzi; F Barbato; M Landriscina; G Storto
Journal:  Biomed Res Int       Date:  2016-08-03       Impact factor: 3.411

Review 7.  Transarterial Radioembolization (TARE) Agents beyond 90Y-Microspheres.

Authors:  C Bouvry; X Palard; J Edeline; V Ardisson; P Loyer; E Garin; N Lepareur
Journal:  Biomed Res Int       Date:  2018-12-31       Impact factor: 3.246

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.